Sandbox ID Systemic: Difference between revisions
Jump to navigation
Jump to search
Gerald Chi- (talk | contribs) mNo edit summary |
|||
| Line 13: | Line 13: | ||
===Brucellosis=== | ===Brucellosis=== | ||
===Cancer-related infection, prophylaxis=== | |||
===Cancer-related infection, treatment=== | |||
===Diptheria=== | ===Diptheria=== | ||
===Ehrlichiolsis=== | ===Ehrlichiolsis=== | ||
===Kawasaki syndrome=== | ===Kawasaki syndrome=== | ||
| Line 29: | Line 29: | ||
===Lymphangitis=== | ===Lymphangitis=== | ||
===Neutropenic fever=== | |||
===Relapsing fever=== | ===Relapsing fever=== | ||
| Line 36: | Line 38: | ||
===Salmonella bacteremia=== | ===Salmonella bacteremia=== | ||
===Sepsis=== | ===Sepsis, adult=== | ||
===Sepsis, pediatric=== | |||
===Staphylococcal toxic shock syndrome=== | ===Staphylococcal toxic shock syndrome=== | ||
Revision as of 03:58, 14 June 2015
Anaplasmosis
Babesiosis
- Preferred regimen (1): Combined therapy with Clindamycin and Quinine
- Preferred regimen (2): Both atovaquone (a hydroxy-1,4-naphthoquinone) alone and azithromycin (an azalide macrolide) alone appeared to be effective.
- Note : Neither the regimen of atovaquone and azithromycin nor the regimen of clindamycin and quinine clears Babesiosis microti merozoites from the human blood as rapidly as might be desired.